drugset
drugset / Trial / NCT03878524

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

NCT03878524 ↗

Phase 1 Terminated 2 enrolled OHSU Knight Cancer Institute Oregon Health and Science University · collab
NaSingle-groupOpen-labelTreatment

Summary

This phase Ib trial determines if samples from a patient's cancer can be tested to find combinations of drugs that provide clinical benefit for the kind of cancer the patient has. This study is also being done to understand why cancer drugs can stop working and how different cancers in different people respond to different types of therapy.

Timeline

Start
2020-04-01
Primary completion
2020-12-10
Completion
2020-12-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Abemaciclib Small molecule — Oral
Subject Abiraterone acetate Small molecule — Oral
Subject Afatinib Small molecule — Oral
Subject Bevacizumab Monoclonal antibody — Intravenous
Subject Bicalutamide Other / unclassified — Oral
Subject Bortezomib Small molecule — Intravenous
Subject Cabazitaxel Other / unclassified — Intravenous
Subject Cabozantinib Small molecule — Oral
Subject Capecitabine Small molecule — Oral
Subject Carboplatin Small molecule — Intravenous
Subject Celecoxib Other / unclassified — Oral
Subject Cobimetinib Small molecule — Oral
Subject Copanlisib Small molecule — Intravenous
Subject DACOMITINIB ANHYDROUS Small molecule — Oral
Subject Dabrafenib Small molecule — Oral
Subject Darolutamide Other / unclassified — Oral
Subject Doxorubicin Other / unclassified — Intravenous
Subject Durvalumab Monoclonal antibody — Intravenous
Subject Enasidenib Small molecule — Oral
Subject Entrectinib Small molecule — Oral
Subject Enzalutamide Other / unclassified — Oral
Subject Erlotinib Small molecule — Oral
Subject Everolimus Small molecule — Oral
Subject Idelalisib Small molecule — Oral
Subject Imatinib Small molecule — Oral
Subject Ipilimumab Monoclonal antibody — Intravenous
Subject Lenvatinib Small molecule — Oral
Subject Leucovorin Small molecule — Intravenous
Subject Lorlatinib Small molecule — Oral
Subject Losartan Other / unclassified — Oral
Subject Neratinib Small molecule — Oral
Subject Nivolumab Monoclonal antibody — Intravenous
Subject Olaparib Small molecule — Oral
Subject Oxaliplatin Small molecule — Intravenous
Subject Paclitaxel Small molecule — Intravenous
Subject Palbociclib Small molecule — Oral
Subject Panobinostat Small molecule — Oral
Subject Pembrolizumab Monoclonal antibody — Intravenous
Subject Pertuzumab Monoclonal antibody — Intravenous
Subject Ponatinib Small molecule — Oral
Subject Regorafenib Small molecule — Oral
Subject Ruxolitinib Small molecule — Oral
Subject Sirolimus Small molecule — Oral
Subject Sorafenib Small molecule — Oral
Subject Sunitinib Small molecule — Oral
Subject Trametinib Small molecule — Oral
Subject Trastuzumab emtansine Other / unclassified — Intravenous
Subject Tretinoin Small molecule — Oral
Subject Vemurafenib Small molecule — Oral
Subject Venetoclax Small molecule — Oral
Subject Vismodegib Small molecule — Oral
Subject Vorinostat Small molecule — Oral
Subject dasatinib anhydrous Small molecule — Oral
Subject fluorouracil Small molecule — Intravenous

Indications

acute myeloid leukemia atypical chronic myeloid leukemia, BCR-ABL1 negative blast phase chronic myelogenous leukemia, BCR-ABL1 positive castration-resistant prostate carcinoma chronic lymphocytic leukemia/small lymphocytic lymphoma chronic myelomonocytic leukemia classic Hodgkin lymphoma female breast carcinoma invasive breast carcinoma leukemia, myeloid, accelerated-phase metastatic malignant neoplasm myelodysplastic syndrome myeloproliferative neoplasm, unclassifiable pancreatic adenocarcinoma plasma cell myeloma primary myelofibrosis primary organ-specific lymphoma refractory malignant neoplasm